2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
First Claim
Patent Images
1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:
7 Assignments
0 Petitions
Accused Products
Abstract
The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
-
Citations
45 Claims
- 1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:
- 4. A pharmaceutical composition comprising an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof to treat a Flaviviridae infection, in a pharmaceutically acceptable carrier.
- 19. A method of treating a host infected with a flavivirus or pestivirus, comprising administering to a host in need thereof an effective amount of a compound having the structure of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof optionally in a pharmaceutically acceptable carrier.
-
37. A compound of Formula I or II, wherein the 5′
- -hydroxyl group is replaced with a 5′
-OR, wherein R is phosphate;
a stabilized phosphate prodrug;
acyl;
alkyl;
sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted;
a lipid;
an amino acid;
a carbohydrate;
a peptide;
cholesterol;
or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R is independently H or phosphate.
- -hydroxyl group is replaced with a 5′
-
38. A pharmaceutical composition that comprises the compound of Formula I or II in a pharmaceutically acceptable carrier, wherein the 5′
- -hydroxyl group is replaced with a 5′
-OR, wherein R is phosphate;
a stabilized phosphate prodrug;
acyl;
alkyl;
sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and;
benzyl, wherein the phenyl group is optionally substituted;
a lipid, an amino acid;
a carbohydrate;
a peptide;
a cholesterol;
or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R is independently H or phosphate.
- -hydroxyl group is replaced with a 5′
-
39. A method for treating a host infected with an RNA-dependant RNA polymerase virus, comprising administering an effective amount of the compound of Formula I or II in a pharmaceutically acceptable carrier, wherein the 5′
- -hydroxyl group is replaced with a 5′
-OR, wherein R is hydrogen, phosphate;
a stabilized phosphate prodrug;
acyl;
alkyl;
sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and;
benzyl, wherein the phenyl group is optionally substituted;
a lipid, an amino acid;
a carbohydrate;
a peptide;
a cholesterol;
or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R is independently H or phosphate. - View Dependent Claims (40, 41, 42)
- -hydroxyl group is replaced with a 5′
Specification